Prescription Drug Use Plunges in Legal Cannabis States

1.7 min readPublished On: April 25th, 2022By

LOS ANGELES- According to a Cornell researcher, legalizing recreational cannabis reduces demand for expensive prescription medications through state Medicaid programs.

The amount of prescriptions for pain, depression, anxiety, sleep, psychosis, and seizures decreases dramatically when states legalize cannabis, according to the study.

The research was carried out by Shyam Raman, a PhD student at Cornell’s Jeb E. Brooks School of Public Policy, and Ashley Bradford, a doctoral student at Indiana University. Their study was published in the journal Health Economics on April 15 and is titled “Recreational Cannabis Legalizations Associated with Reductions in Prescription Drug Utilization Among Medicaid Enrollees.”

The majority of cannabis research has focused on the influence of medicinal cannabis on prescription drug demand or the impact of legalizing recreational cannabis on opioid demand. This is one of the first studies to look at how legal personal-use cannabis affects a wide range of prescription medications.

“These findings have far-reaching ramifications,” Raman explained. “The decreases in drug usage that we discover could result in significant cost savings for state Medicaid programs.” The findings also point to a way to lessen the harm caused by serious side effects associated with some prescription medicines.”

Raman and Bradford based their research on an examination of data from the Centers for Medicare and Medicaid Services in all 50 states from 2011 to 2019, a time during which the number of states allowing personal cannabis use increased.
Around 40 states have approved medical cannabis, which requires a doctor’s prescription. About 20 states have allowed personal-use cannabis for all adults so far, but that number is expected to grow. Raman and Bradford discovered a significant change in demand for medications to treat sleep and anxiety disorders in such states, but no effect on drugs to alleviate nausea.

Raman and Bradford point out that cannabis usage is not without risk, citing numerous research that link it to the onset of anxiety and psychoses like schizophrenia. Furthermore, people who use cannabis to manage their medical ailments may be less likely to contact their doctor, resulting in gaps in primary care.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Medical Marijuana Market

Global Medical Marijuana Market Report 2022-2030

October 3rd, 2022|

Dublin - The global medical marijuana market size is expected to reach USD 65.8 billion by 2030 and is expected to expand at a CAGR of 21.6% The major factors attributed to the industry growth ...